scholarly journals Swiss Webster Mouse

2020 ◽  
Author(s):  
Keyword(s):  
Swiss Webster Mouse

scholarly journals SPATIAL AND TEMPORAL EXPRESSION OF HOX PROTEINS IN THE DEVELOPING SWISS WEBSTER MOUSE SMALL INTESTINE. † 242

1997 ◽  
Vol 41 ◽  
pp. 43-43
Author(s):  
Cynthia A. Doyle ◽  
Chiwan Kim ◽  
Mary Ann V. Volpe ◽  
Robert J. Vosatka ◽  
Heber C. Nielsen
Keyword(s):  
Small Intestine ◽  
Temporal Expression ◽  
Hox Proteins ◽  
Mouse Small Intestine ◽  
Swiss Webster Mouse

Teratogenic effects of the demethylating agent 5-aza-2′-deoxycytidine in the Swiss Webster mouse

Toxicology ◽  
1996 ◽  
Vol 112 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Stacy Branch ◽  
Bettina M. Francis ◽  
Cecil F. Brownie ◽  
Neil Chernoff
Keyword(s):  
Teratogenic Effects ◽  
Demethylating Agent ◽  
Swiss Webster Mouse

Curcumin modulates drug metabolizing enzymes in the female Swiss Webster mouse

Life Sciences ◽  
2006 ◽  
Vol 78 (20) ◽  
pp. 2391-2398 ◽  
Author(s):  
Sophie P. Valentine ◽  
Martin J. Le Nedelec ◽  
Anna R. Menzies ◽  
Marissa J. Scandlyn ◽  
Mette G. Goodin ◽  
...  
Keyword(s):  
Drug Metabolizing Enzymes ◽  
Metabolizing Enzymes ◽  
Swiss Webster Mouse

scholarly journals Characterization of cerebral malaria in the outbred Swiss Webster mouse infected byPlasmodium bergheiANKA

2009 ◽  
Vol 90 (2) ◽  
pp. 119-130 ◽  
Author(s):  
Yuri Chaves Martins ◽  
Mary Jane Smith ◽  
Marcelo Pelajo-Machado ◽  
Guilherme Loureiro Werneck ◽  
Henrique Leonel Lenzi ◽  
...  
Keyword(s):  
Cerebral Malaria ◽  
Swiss Webster Mouse

scholarly journals Establishment of a Swiss Webster Mouse Model of Pneumonic Plague To Meet Essential Data Elements under the Animal Rule

2012 ◽  
Vol 19 (4) ◽  
pp. 468-476 ◽  
Author(s):  
Patricia Fellows ◽  
Winston Lin ◽  
Carol Detrisac ◽  
Shu-Chieh Hu ◽  
Narayanan Rajendran ◽  
...  
Keyword(s):  
Mouse Model ◽  
Lethal Dose ◽  
Clinical Signs ◽  
Probit Analysis ◽  
Exposure System ◽  
Pneumonic Plague ◽  
Aerosol Exposure ◽  
Swiss Webster Mouse ◽  
Data Elements ◽  
Animal Rule

ABSTRACTA recombinant vaccine (rF1V) is being developed for protection against pneumonic plague. This study was performed to address essential data elements to establish a well-characterized Swiss Webster mouse model for licensing the rF1V vaccine using the FDA's Animal Rule. These elements include the documentation of challenge material characteristics, aerosol exposure parameters, details of the onset and severity of clinical signs, pathophysiological response to disease, and relevance to human disease. Prior to animal exposures, an evaluation of the aerosol system was performed to determine and understand the variability of the aerosol exposure system. Standardized procedures for the preparation ofYersinia pestischallenge material also were developed. The 50% lethal dose (LD50) was estimated to be 1,966 CFU using Probit analysis. Following the LD50determination, pathology was evaluated by exposing mice to a target LD99(42,890 CFU). Mice were euthanized at 12, 24, 36, 48, 60, and 72 h postexposure. At each time point, samples were collected for clinical pathology, detection of bacteria in blood and tissues, and pathology evaluations. A general increase in incidence and severity of microscopic findings was observed in the lung, lymph nodes, spleen, and liver from 36 to 72 h postchallenge. Similarly, the incidence and severity of pneumonia increased throughout the study; however, some mice died in the absence of pneumonia, suggesting that disease progression does not require the development of pneumonia. Disease pathology in the Swiss Webster mouse is similar to that observed in humans, demonstrating the utility of this pneumonic plague model that can be used by researchers investigating plague countermeasures.

Sign in / Sign up

Export Citation Format

Share Document